338 related articles for article (PubMed ID: 9839090)
21. [In vivo pharmacokinetic of amikacin and its pharmacodynamic in combination with cefepime, cefpirome and meropenem in an in vitro/ex vivo micropig model].
Elkhaïli H; Pompei D; Peter JD; Linger L; Salmon J; Levêque D; Niedergang S; Salmon Y; Thierry RC; Monteil H; Jehl F
Pathol Biol (Paris); 1997 May; 45(5):347-56. PubMed ID: 9296083
[TBL] [Abstract][Full Text] [Related]
22. The pharmacodynamics of beta-lactams.
Turnidge JD
Clin Infect Dis; 1998 Jul; 27(1):10-22. PubMed ID: 9675443
[TBL] [Abstract][Full Text] [Related]
23. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
[TBL] [Abstract][Full Text] [Related]
24. Once-a-day cephalosporins: reality or myth?
Scaglione F; Dugnani S; Fraschini F
J Chemother; 1995 May; 7 Suppl 1():13-5. PubMed ID: 8618107
[TBL] [Abstract][Full Text] [Related]
25. Beta-lactams in continuous infusion for Gram-negative bacilli osteoarticular infections: an easy method for clinical use.
Ribera A; Soldevila L; Rigo-Bonnin R; Tubau F; Padullés A; Gómez-Junyent J; Ariza J; Murillo O
Infection; 2018 Apr; 46(2):239-244. PubMed ID: 29363049
[TBL] [Abstract][Full Text] [Related]
26. A Review of Extended and Continuous Infusion Beta-Lactams in Pediatric Patients.
Imburgia TA; Kussin ML
J Pediatr Pharmacol Ther; 2022; 27(3):214-227. PubMed ID: 35350159
[TBL] [Abstract][Full Text] [Related]
27. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
Jpn J Antibiot; 2003 Oct; 56(5):458-96. PubMed ID: 14692381
[TBL] [Abstract][Full Text] [Related]
28. Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters.
Kasiakou SK; Lawrence KR; Choulis N; Falagas ME
Drugs; 2005; 65(17):2499-511. PubMed ID: 16296874
[TBL] [Abstract][Full Text] [Related]
29. Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role.
Roberts JA; Paratz J; Paratz E; Krueger WA; Lipman J
Int J Antimicrob Agents; 2007 Jul; 30(1):11-8. PubMed ID: 17442541
[TBL] [Abstract][Full Text] [Related]
30. Pharmacodynamics of doripenem in critically ill patients with ventilator-associated Gram-negative bacilli pneumonia.
Jaruratanasirikul S; Wongpoowarak W; Kositpantawong N; Aeinlang N; Jullangkoon M
Int J Antimicrob Agents; 2012 Nov; 40(5):434-9. PubMed ID: 22959555
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections.
Pai MP; Cojutti P; Pea F
Clin Pharmacokinet; 2015 Sep; 54(9):933-41. PubMed ID: 25850987
[TBL] [Abstract][Full Text] [Related]
32. Who should receive extended infusion beta-lactam therapy?
Roman C; Solh T; Damer KM
JAAPA; 2016 Mar; 29(3):25-6. PubMed ID: 26914778
[TBL] [Abstract][Full Text] [Related]
33. Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis.
Prescott WA; Gentile AE; Nagel JL; Pettit RS
P T; 2011 Nov; 36(11):723-63. PubMed ID: 22346306
[TBL] [Abstract][Full Text] [Related]
34. Cefpirome clinical pharmacokinetics.
Strenkoski LC; Nix DE
Clin Pharmacokinet; 1993 Oct; 25(4):263-73. PubMed ID: 8261711
[TBL] [Abstract][Full Text] [Related]
35. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?
Pea F; Della Siega P; Cojutti P; Sartor A; Crapis M; Scarparo C; Bassetti M
Int J Antimicrob Agents; 2017 Feb; 49(2):255-258. PubMed ID: 28012683
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of beta-lactam antibiotics in patients with intra-abdominal disease: a structured review.
Adnan S; Paterson DL; Lipman J; Kumar S; Li J; Rudd M; Roberts JA
Surg Infect (Larchmt); 2012 Feb; 13(1):9-17. PubMed ID: 22316144
[TBL] [Abstract][Full Text] [Related]
37. Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization.
Cojutti PG; Gatti M; Rinaldi M; Tonetti T; Laici C; Mega C; Siniscalchi A; Giannella M; Viale P; Pea F
Front Pharmacol; 2021; 12():781892. PubMed ID: 34955851
[No Abstract] [Full Text] [Related]
38. Mycobacterium abscessus l,d-Transpeptidases Are Susceptible to Inactivation by Carbapenems and Cephalosporins but Not Penicillins.
Kumar P; Chauhan V; Silva JRA; Lameira J; d'Andrea FB; Li SG; Ginell SL; Freundlich JS; Alves CN; Bailey S; Cohen KA; Lamichhane G
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760902
[TBL] [Abstract][Full Text] [Related]
39. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients.
Cheatham SC; Shea KM; Healy DP; Humphrey ML; Fleming MR; Wack MF; Smith DW; Sowinski KM; Kays MB
Int J Antimicrob Agents; 2011 Jan; 37(1):46-50. PubMed ID: 21074370
[TBL] [Abstract][Full Text] [Related]
40. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
Andes D; Craig WA
Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
